Normalised Returns
Cement & Cement Products · closest in market valueAMBUJACEM−31.7%Nifty 50−6.1%
Full Comparison
NSE filings · last close| Company | Price | Mkt Cap | P/E | P/B | ROE | Margin | Rev YoY | PAT YoY | D/E | 1Y Rtn |
|---|---|---|---|---|---|---|---|---|---|---|
| ULTRACEMCO | ₹11,155 | ₹3.29L Cr | 38.4× | 4.29× | 11.1% | 9.3% | +15.9% | +17.2% | 0.30× | −7.4% |
| GRASIM | ₹3,191 | ₹2.17L Cr | 19.1× | 2.10× | 10.3% | 5.9% | +21.4% | +39.0% | 2.17× | +16.2% |
| AMBUJACEM ● | ₹383.8 | ₹94,868 Cr | 18.3× | 1.60× | 10.0% | 13.9% | −7.7% | −31.9% | 0.00× | −31.7% |
| SHREECEM | ₹22,520 | ₹81,252 Cr | 49.7× | 3.49× | 7.8% | 8.3% | +18.0% | −17.5% | 0.07× | −24.3% |
| JKCEMENT | ₹5,000 | ₹38,635 Cr | 41.2× | 5.49× | 15.1% | 7.2% | +20.3% | −15.3% | 0.86× | −20.8% |
| DALBHARAT | ₹1,700 | ₹32,304 Cr | 33.9× | 1.80× | 6.5% | 7.8% | +7.0% | −51.4% | 0.38× | −23.7% |
Cement & Cement Products: the companies closest in market value, of the 31 in that basic industry whose filings we hold, from each company's NSE filings and the last close. Quarterly figures are for Q1 FY27; ROE, margin for FY26; P/B and D/E on the latest balance sheet. Green and red mark the two ends of a column; valuation and leverage columns are left plain. Hover a heading for its definition.
Against Cement & Cement Products31 companies
P/E18.8×
8.35×median 27.6× · 18 of 25, highest first134.0×
P/B1.64×
0.47×median 1.64× · 15 of 30, highest first5.59×
ROE8.7%
-91.0%median 8.2% · 14 of 30, highest first13.6%
Net margin13.0%
-38.2%median 5.5% · 1 of 30, highest first13.0%
Revenue growth7.7%
-15.9%median 8.6% · 17 of 29, highest first56.4%
Profit growth-3.0%
-70.9%median 1.1% · 14 of 23, highest first182.9%
Debt / equity0.00×
0.00×median 0.41× · 28 of 30, highest first13.8×
Dividend yield0.5%
0.1%median 0.6% · 14 of 21, highest first5.2%
1-year price change-33.8%
-52.2%median -26.6% · 23 of 30, highest first39.0%
Everyone in Cement & Cement Products whose filings we hold: 31 companies, its basic industry within Construction Materials. Figures as the screener works them out (the last four quarters' profit, the latest balance sheet, the last close), so ROE can differ a little from the Financials tab's latest-year figure. A place in the line is a fact about a number, not a view on the company.
AMBUJACEM Rankings
Among 6 companies compared
Profitability
4
ROE 10.0%4th highest of 61
Net margin 13.9%Highest of 6Growth
6
Revenue YoY −7.7%Lowest of 65
Net profit YoY −31.9%5th highest of 6Leverage
1
Debt / equity 0.00×Lowest of 6Valuation
1
P/E 18.3×Lowest of 61
P/Book 1.60×Lowest of 6Price
6
1-year return −31.7%Lowest of 6Position 1 is the lowest NPA, multiple or leverage, and the highest return, growth or profitability figure. These are positions among the companies listed here, not a view on the stock.